title: Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
abstract: Glioblastoma multiforme (GBM) is the most malignant World Health Organization grade IV brain tumor. GBM patients have a poor prognosis because of its resistance to standard therapies, such as chemotherapy and radiation. Since stem-like cells have been associated with the treatment resistance of GBM, novel therapies targeting the cancer stem cell (CSC) population is critically required. However, GBM CSCs share molecular and functional characteristics with normal neural stem cells (NSCs). To elucidate differential therapeutic targets of GBM CSCs, we compared surface markers of GBM CSCs with adult human NSCs and found that GD2 and CD90 were specifically overexpressed in GBM CSCs. We further tested whether the GBM CSC specific markers are associated with the cancer stemness using primarily cultured patient-derived GBM cells. However, results consistently indicated that GBM cells with or without GD2 and CD90 had similar in vitro sphere formation capacity, a functional characteristics of CSCs. Therefore, GD2 and CD90, GBM specific surface markers, might not be used as specific therapeutic targets for GBM CSCs, although they could have other clinical utilities.
authors: Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea. ; Center for Molecular Medicine, Samsung Biomedical Research Institute, Seoul, Korea.
authors: Seon Rang
authors: SR
authors: Woo
authors: Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea. ; Center for Molecular Medicine, Samsung Biomedical Research Institute, Seoul, Korea.
authors: Young Taek
authors: YT
authors: Oh
authors: Department of Anatomy and Cell Biology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors: Jae Yeol
authors: JY
authors: An
authors: Department of Anatomy and Cell Biology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors: Bong Gu
authors: BG
authors: Kang
authors: Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea. ; Center for Molecular Medicine, Samsung Biomedical Research Institute, Seoul, Korea. ; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors: Do-Hyun
authors: DH
authors: Nam
authors: Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul, Korea. ; Center for Molecular Medicine, Samsung Biomedical Research Institute, Seoul, Korea. ; Department of Anatomy and Cell Biology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors: Kyeung Min
authors: KM
authors: Joo
keywords: CD90; Cancer stem cell; GD2; Glioblastoma multiforme; Therapeutic marker